Informazione: Due to increasing bot activity we were unfortunately forced to place the search behind a login. Links to models can still be shared with others and viewed without a login. Thank you for your understanding.
Informazione:
Errore:
ID
30257
Descrizione
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00634088
collegamento
https://clinicaltrials.gov/show/NCT00634088
Keywords
versioni (1)
- 25/05/18 25/05/18 -
Titolare del copyright
See clinicaltrials.gov
Caricato su
25 maggio 2018
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Eligibility Locally Advanced or Metastatic Breast Cancer NCT00634088
Eligibility Locally Advanced or Metastatic Breast Cancer NCT00634088
- StudyEvent: Eligibility
Similar models
Eligibility Locally Advanced or Metastatic Breast Cancer NCT00634088
- StudyEvent: Eligibility
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Gender | Age | Breast adenocarcinoma
Item
females aged 18 years or older with histologic or cytologic diagnosis of adenocarcinoma originating in the breast
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0858252 (UMLS CUI [3])
C0001779 (UMLS CUI [2])
C0858252 (UMLS CUI [3])
Neoplasm Metastasis TNM clinical staging | Locally Advanced Malignant Neoplasm TNM clinical staging | Incurable disease | Therapeutic radiology procedure Unsuccessful | Operative Surgical Procedures Unsuccessful
Item
radiologic or pathologic evidence that the cancer is metastatic or locally advanced (a t4 tumor and stage iiib/iiic disease) and not curable by local measures, such as radiation or surgery
boolean
C0027627 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0677984 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C0175969 (UMLS CUI [3])
C1522449 (UMLS CUI [4,1])
C1272705 (UMLS CUI [4,2])
C0543467 (UMLS CUI [5,1])
C1272705 (UMLS CUI [5,2])
C3258246 (UMLS CUI [1,2])
C0677984 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C0175969 (UMLS CUI [3])
C1522449 (UMLS CUI [4,1])
C1272705 (UMLS CUI [4,2])
C0543467 (UMLS CUI [5,1])
C1272705 (UMLS CUI [5,2])
HER2/Neu Positive
Item
positive status for human epidermal growth factor receptor 2
boolean
C2348909 (UMLS CUI [1])
Measurable Disease
Item
measurable disease as per response evaluation criteria in solid tumors guidelines
boolean
C1513041 (UMLS CUI [1])
Karnofsky Performance Status
Item
karnofsky performance status of 70 to 100
boolean
C0206065 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 3 months
boolean
C0023671 (UMLS CUI [1])
Irradiation of pelvis Bone Marrow Percentage | Prior radiation therapy Lumbar spine Bone Marrow Percentage
Item
prior radiation must not have included 30% or more of major bone-marrow containing areas, such as the pelvis and lumbar spine
boolean
C0747411 (UMLS CUI [1,1])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C0024091 (UMLS CUI [2,2])
C0005953 (UMLS CUI [2,3])
C0439165 (UMLS CUI [2,4])
C0005953 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
C0279134 (UMLS CUI [2,1])
C0024091 (UMLS CUI [2,2])
C0005953 (UMLS CUI [2,3])
C0439165 (UMLS CUI [2,4])
Neuropathy CTCAE Grades
Item
common terminology criteria grade 2 or greater neuropathy
boolean
C0442874 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,2])
Hematologic function | Liver function | Renal function
Item
inadequate hematologic, hepatic, or renal function
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Severe allergy Cremophor EL Pharmaceutical Preparations | Hypersensitivity Fluoropyrimidine | Intolerance to Fluoropyrimidine
Item
known prior severe hypersensitivity reactions to agents containing cremophor® el or known hypersensitivity or prior intolerance to fluoropyrimidine
boolean
C2945656 (UMLS CUI [1,1])
C0056476 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0596581 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C0596581 (UMLS CUI [3,2])
C0056476 (UMLS CUI [1,2])
C0013227 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0596581 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C0596581 (UMLS CUI [3,2])
Dihydropyrimidine Dehydrogenase Deficiency | Dihydropyrimidine Dehydrogenase Deficiency Suspected
Item
known or suspected dihydropyrimidine dehydrogenase deficiency
boolean
C1959620 (UMLS CUI [1])
C1959620 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C1959620 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
Chemotherapy Regimen Quantity Neoplasm Metastasis
Item
more than 3 prior chemotherapy regimens in the metastatic setting
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
C1265611 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,3])
Epothilone | lapatinib | capecitabine
Item
prior treatment with an epothilone or lapatinib; prior treatment with capecitabine within the past 6 months
boolean
C1136012 (UMLS CUI [1])
C1506770 (UMLS CUI [2])
C0671970 (UMLS CUI [3])
C1506770 (UMLS CUI [2])
C0671970 (UMLS CUI [3])